A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Clinical Trial ID NCT01496742

Rank	Title	Journal	Year	PubWeight™‹?›
1	Controlling escape from angiogenesis inhibitors.	Nat Rev Cancer	2012	1.81
2	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.	J Cancer	2013	1.31
3	Targeted therapy for non-small-cell lung cancer: past, present and future.	Expert Rev Anticancer Ther	2013	1.22
4	Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.	Semin Oncol	2013	1.03
5	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.	Pharmgenomics Pers Med	2015	0.88
6	MET inhibition in lung cancer.	Transl Lung Cancer Res	2013	0.82
7	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.	Ann Transl Med	2015	0.81
8	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?	J Cancer	2016	0.79
9	Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.	PLoS One	2015	0.78
10	MET inhibitors in combination with other therapies in non-small cell lung cancer.	Transl Lung Cancer Res	2012	0.78
11	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.	Eur J Cardiothorac Surg	2015	0.77